Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Duke Univ

Neither a doctor nor a teaching hospital

Research payments

$4,896,904

500 payments

Through program year 2025, Duke Univ is reported as receiving $4,896,904 in research payments, across 500 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $497,336 58
2024 Research $479,633 45
2023 Research $648,707 30
2022 Research $672,169 18
2021 Research $194,896 28
2020 Research $299,379 202
2019 Research $2,104,783 119

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,366,871 26 payments
  2. Janssen Research & Development, LLC $1,462,508 149 payments
  3. Alexion Pharmaceuticals, Inc. $384,986 8 payments
  4. Novo Nordisk AS $239,191 300 payments
  5. Novo Nordisk Inc $200,000 2 payments
  6. Astellas Pharma Global Development $91,246 4 payments
  7. Merck Sharp & Dohme Corporation $63,563 2 payments
  8. Lexicon Pharmaceuticals, Inc. $35,965 1 payment
  9. AstraZeneca UK Limited $28,616 3 payments
  10. Actelion Pharmaceuticals, Ltd $17,662 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Single Arm Phase II Study Osimertinib in Patients with Advanced Non-small Cell Lung Cancer with Uncommon EGFR Mutations $1,673,882 3 payments
  2. Phase 3 Multi Center Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis $850,881 31 payments
  3. Phase II Multicenter Study of Durvalumab (MEDI4736) and Olaparib in Platinum Treated Advanced Triple Negative Breast Cancer - DORA $610,096 2 payments
  4. Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study $236,818 44 payments
  5. Assoc b/n weight change and cardiometabolic risk factors in a real-world population of US Adults $200,000 2 payments
  6. Nn9931-4492 $138,292 200 payments
  7. Targeting Complement C3 to Prevent Acute Antibody Medicated Rejection for a Deceased Donor Kidney Transplant in Sensitized Recipients $111,313 1 payment
  8. Complement Activation Assay in ITP Immune Thrombocytopenia Patient Samples $103,684 1 payment
  9. Ex9536-4388 $91,822 92 payments
  10. Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene $91,476 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record